摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+ ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要翻译:本发明涉及包含作为胃酸分泌抑制剂的不可逆胃H + / K + ATP酶质子泵抑制剂(PPI)和作为胃内腔壁细胞激活剂的一种或多种小羧酸分子的新型口服组合物。 意外地,本发明的组合物能够增强胃中PPI的抗酸活性。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要翻译:本发明涉及包含作为胃酸分泌抑制剂的不可逆胃H + / K + -ATP酶质子泵抑制剂(PPI)和作为胃内腔壁细胞活化剂的一种或多种小羧酸分子的新型口服组合物。 意外地,本发明的组合物能够增强胃中PPI的抗酸活性。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要翻译:本发明涉及包含作为胃酸分泌抑制剂的不可逆胃H + / K + -ATP酶质子泵抑制剂(PPI)和作为胃内腔壁细胞活化剂的一种或多种小羧酸分子的新型口服组合物。 意外地,本发明的组合物能够增强胃中PPI的抗酸活性。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity compared to the non-derivatized acid molecules. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要翻译:本发明涉及包含不可逆胃H + / K + -ATP酶质子泵抑制剂(PPI)作为胃酸分泌抑制剂和一种或多种活化壁细胞的脂肪族羧酸衍生物分子的新型口服组合物,其中衍生物具有延迟或 与未衍生的酸分子相比,PPI活性持续增强作用。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要翻译:本发明涉及包含作为胃酸分泌抑制剂的不可逆胃H + / K + -ATP酶质子泵抑制剂(PPI)和作为胃内腔壁细胞活化剂的一种或多种小羧酸分子的新型口服组合物。 意外地,本发明的组合物能够增强胃中PPI的抗酸活性。 本发明还涉及使用这种组合物以减少哺乳动物胃酸分泌的方法。
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
摘要:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.